[Calciphylaxis in dialysis patients: To recognize and treat it as soon as possible].
Calciphylaxis (CPX) or calcific uraemic arteriolopathy is a rare life-threatening complication, affecting mainly dialysis patients. The condition is characterized by calcifications and thrombosis of the small cutaneous vessels and small vessels in the fat tissue, resulting in the development of necrotizing and non-healing ulcers. The development of these lesions leads to poor outcomes owing to infectious complications and some frequently associated unfavourable medical conditions: obesity, diabetes, and peripheral vascular disease. We report the case of six patients with different clinical forms of CPX in the past 10 years with favourable outcomes observed in five of the six patients. The diagnosis was based on clinical presentation: bilateral and hyperalgesic necrotic lesions along with a history of mineral metabolism disorder or warfarin use. The therapeutic strategy included the following: daily dialysis, hyperbaric oxygen therapy, treatment of limb artery stenosis, maintenance of the optimal haemodynamic stability, delivery of cutaneous care, administration of analgesics and antibiotics, warfarin and calcium cessation, and additional therapy with cinacalcet or parathyroidectomy and therapy with bisphosphonates or sodium thiosulphate. Healing was observed in five out of six CPX patients by using this strategy that should be rapidly employed in order to decrease the necrotizing areas that result in poor outcomes. Prevention includes identification of at-risk patients in order to optimize the treatment of the identified risk factors for CPX.
Jean
Guillaume
G
Centre de rein artificiel, 42, avenue du 8-mai-1945, 69160 Tassin La Demi-Lune, France. guillaume-jean-crat@wanadoo.fr
Terrat
Jean-Claude
JC
Vanel
Thierry
T
Hurot
Jean-Marc
JM
Lorriaux
Christie
C
Mayor
Brice
B
Chazot
Charles
C
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002115:Calciphylaxis / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D006801:Humans; D006931:Hyperbaric Oxygenation; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D017592:Skin Care
D000900:Anti-Bacterial Agents